|
|||
2009-06-24 14:30:00 CEST 2009-06-24 14:30:01 CEST REGULATED INFORMATION Biohit Oyj - Total number of voting rights and capitalNOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10BIOHIT OYJ STOCK EXCHANGE RELEASE, 24 JUNE 2009 at 3:30 PM NOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10 In accordance with the Securities Markets Act, Chapter 2, Section 9, Biohit Oyj today received notification that the combined share of voting rights conferred by shares owned by Professor Pentti Sipponen and Patolab Oy - a company in his control - has fallen to under one twentieth. In a transaction made on 24 June 2009, ownership of a total of 900,000 Series B shares held by Pentti Sipponen was transferred to Biocosmos Oy (450,000 shares) and Interlab Oy (450,000 shares) - two companies under the control of Professor Osmo Suovaniemi. In accordance with the Securities Markets Act, Chapter 2, Section 10, Biohit Oyj is issuing notification that, as a result of the above transaction, the percentage of shares and votes held by Pentti Sipponen and any companies in his control are as follows: -------------------------------------------------------------------------------- | | Number of | % of shares | % of votes | | | shares | | | -------------------------------------------------------------------------------- | Pentti Sipponen | | | | -------------------------------------------------------------------------------- | Series B shares | 0 | 0.00 | 0.00 | -------------------------------------------------------------------------------- | Patolab Oy | | | | | (Business ID 0427816-5) | | | | -------------------------------------------------------------------------------- | Series B shares | 12,300 | 0.10 | 0.01 | -------------------------------------------------------------------------------- | Total | 12,300 | 0.10 | 0.01 | -------------------------------------------------------------------------------- Biohit Oyj's share capital consists of a total of 12,937,627 shares (2,975,500 Series A shares and 9,962,127 Series B shares). Series A shares confer twenty (20) votes and Series B shares confer one (1) vote. In payment of dividends, however, a dividend of two (2) per cent higher than the nominal value is paid for Series B shares than is paid for Series A shares. Biohit Oyj Osmo Suovaniemi President and CEO Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 GSM: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Distribution: Helsinki Exchanges Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Biohit Oyj develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories. Liquid handling products include electronic and mechanical pipettes and dispensers, and disposable tips, as well as pipette maintenance and calibration services. Diagnostics business comprises products and analysis systems for diagnosing, screening and prevention of gastrointestinal diseases, e.g. the blood-sample based GastroPanel and GastroView, for diagnosing diseases of the stomach and associated risks, as well as quick tests for the diagnosis of lactose intolerance, H. pylori infection and fecal occult blood. Biohit Group employs 370 people in 8 countries. Biohit Oyj is headquartered in Finland. Subsidiaries are located in France, Germany, the UK, Russia, China, Japan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's share (BIOBV) is quoted on NASDAQ OMX Helsinki. Read more at www.biohit.com |
|||
|